Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome
Open Access
- 8 September 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (1) , 254-262
Abstract
Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder characterized by high titers of antibodies against glutamic acid decarboxylase (GAD) causing impaired GABAergic inhibitory neurotransmission. To date, there is not a defined therapy for such condition, but immunomodulating therapies, such as plasma exchange, intravenous immunoglobulins, and rituximab, have been widely used in clinical practice. However, the efficacy and tolerability of these treatments is not well established. Efgartigimod, a new neonatal Fc receptor (FcRn) blocker, is a human IgG1 antibody Fc fragment engineered with increased affinity for FcRn binding, leading to a reduction in IgGs levels, including pathogenic IgG autoantibody showing promising results in neurological autoimmune disorders and has been approved for the treatment of AChR-seropositive generalized myasthenia gravis (MG). In this study, we report and describe the first data on treatment with efgartigimod in three patients affected by both AChR-seropositive generalized MG and anti-GAD-seropositive SPS. Patients were followed since the start of efgartigimod and for the whole treatment period (12 weeks). MG symptoms were assessed with the “MG activity of daily living score” and the Quantitative Myasthenia Gravis score, while SPS ones were assessed with the “SPS activity of daily living score”; muscle strength was assessed with the Medical Research Council Sum score; the overall disability from MG and SPS was assessed by the modified Rankin Scale. All patients showed an improvement in symptoms of both SPS and MG after 2 cycles of treatment. Our data suggest that efgartigimod may be considered as a candidate drug for SPS and other autoantibody-mediated neurological disorders.Keywords
Funding Information
- Università degli Studi di Palermo
This publication has 28 references indexed in Scilit:
- Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravisExperimental Neurology, 2019
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisNeurology, 2019
- Stiff-Person Syndrome: A Case Report and Review of the LiteratureBritish and Irish Orthoptic Journal, 2019
- Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune DiseasesTrends in Pharmacological Sciences, 2018
- Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humansJournal of Clinical Investigation, 2018
- Stiff-person syndrome after thymectomy in myasthenia gravis mimicking a post-thymectomy myasthenic crisisNeurology India, 2017
- Myasthenia GravisNew England Journal of Medicine, 2016
- Stiff person syndromePractical Neurology, 2011
- Stiff-person syndrome treated with rituximabBMJ Case Reports, 2010
- Stiff-Person SyndromeJCR: Journal of Clinical Rheumatology, 2010